Literature DB >> 12492738

Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients.

N Broutet1, S Tchamgoué, E Pereira, H Lamouliatte, R Salamon, F Mégraud.   

Abstract

AIM: To study risk factors for failure of Helicobacter pylori eradication treatment.
METHODS: Individual data from 2751 patients included in 11 multicentre clinical trials carried out in France and using a triple therapy, were gathered in a unique database. The 27 treatment regimens were regrouped into four categories.
RESULTS: The global failure rate was 25.8% [95% CI: 24-27]. There was a difference in failure rate between duodenal ulcer patients and non-ulcer dyspeptic patients, 21.9% and 33.7%, respectively (P < 10(-6)). In a random-effect model, the risk factors identified for eradication failure in duodenal ulcer patients (n = 1400) were: to be a smoker, and to have received the group 4 treatment, while to receive a 10 day treatment vs. 7 days protected from failure. In non-ulcer dyspeptic patients (n = 913), the group 2 treatment was associated with failure. In both groups, age over 60 was associated with successful H. pylori eradication. There were less strains resistant to clarithromycin in duodenal ulcer patients than in non-ulcer dyspeptic patients. Clarithromycin resistance predicted failure almost perfectly.
CONCLUSION: Duodenal ulcer and non-ulcer dyspeptic patients should be managed differently in medical practice and considered independently in eradication trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12492738     DOI: 10.1046/j.1365-2036.2003.01396.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  58 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.

Authors:  Antonio Rollan; Juan Pablo Arab; M Constanza Camargo; Roberto Candia; Paul Harris; Catterina Ferreccio; Charles S Rabkin; Juan Cristóbal Gana; Pablo Cortés; Rolando Herrero; Luisa Durán; Apolinaria García; Claudio Toledo; Alberto Espino; Nicole Lustig; Alberto Sarfatis; Catalina Figueroa; Javier Torres; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Antibiotics resistance rate of Helicobacter pylori in Bhutan.

Authors:  Ratha-korn Vilaichone; Yoshio Yamaoka; Seiji Shiota; Thawee Ratanachu-ek; Lotay Tshering; Tomohisa Uchida; Toshio Fujioka; Varocha Mahachai
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

4.  Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.

Authors:  T Suzuki; K Matsuo; A Sawaki; K Wakai; K Hirose; H Ito; T Saito; T Nakamura; K Yamao; N Hamajima; K Tajima
Journal:  Epidemiol Infect       Date:  2006-06-02       Impact factor: 2.451

5.  Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity?

Authors:  Carlos Robles-Jara; Carlos Robles-Medranda; Manuel Moncayo; Byron Landivar; Johnny Parrales
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

Review 6.  One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm.

Authors:  David Y Graham; Yoshio Yamaoka
Journal:  Gut       Date:  2007-07       Impact factor: 23.059

7.  Second-line and third-line trial for helicobacter pylori infection in patients with duodenal ulcers: A prospective, crossover, controlled study.

Authors:  György M Buzás; Hajnalka Györffy; Ilona Széles; Anna Szentmihályi
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

8.  The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam.

Authors:  Tran T Binh; Seiji Shiota; Lam T Nguyen; Dung D Q Ho; Hai H Hoang; Long Ta; Dung T Trinh; Toshio Fujioka; Yoshio Yamaoka
Journal:  J Clin Gastroenterol       Date:  2013-03       Impact factor: 3.062

9.  Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy.

Authors:  Zaigham Abbas; Javed Yakoob; Shahab Abid; Wasim Jafri; Muhammad Islam; Zahid Azam; Imran Hilal
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

Review 10.  Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-02-14       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.